Michael Bagwell, DO
Family Medicine · Senatobia, MSNPI 1558306019
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 735 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 735 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- AbbVie$940
- Boehringer Ingelheim$840
- Johnson & Johnson$799
- plus $6K from 29 others
What the payments were for
- Food & beverage$12,691100%
- Education$460%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 81 | $1,606 |
| Novo Nordisk | 81 | $1,461 |
| Lilly USA, LLC | 91 | $1,278 |
| AbbVie(2 entities) | 59 | $940 |
| Boehringer Ingelheim | 52 | $840 |
| Johnson & Johnson | 49 | $799 |
| GSK | 43 | $715 |
| Amarin Pharma, Inc. | 38 | $644 |
| Amgen | 39 | $615 |
| Bayer | 24 | $603 |
| Pfizer | 36 | $529 |
| Dexcom, Inc. | 11 | $314 |
| Esperion Therapeutics, Inc. | 13 | $313 |
| Abbott | 16 | $304 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $219 |
| Sumitomo Pharma America, Inc. | 9 | $167 |
| Mylan Specialty L.p. | 6 | $165 |
| Merck | 7 | $141 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $136 |
| Sanofi-aventis U.S. LLC | 8 | $126 |
| Teva Pharmaceuticals USA, Inc. | 8 | $124 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $122 |
| Novartis | 6 | $105 |
| Viatris Specialty LLC | 3 | $68 |
| Eisai Inc. | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| Impel Pharmaceuticals Inc. | 3 | $48 |
| Exact Sciences | 3 | $41 |
| Genentech USA, Inc. | 3 | $41 |
| Astellas Pharma US Inc | 2 | $36 |
| Boston Scientific | 1 | $36 |
| IBSA Pharma Inc. | 2 | $33 |
| Heartflow, Inc. | 1 | $19 |
| Vertex | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$225
- Xultophy 100/3.6$123
- Ozempic$121
- Kerendia$120
- NEXLIZET$118
- NEXLETOL$118
- DEXCOM G6 TRANSMITTER$114
- AIRSUPRA$100
How this compares
$12,738 in reported general payments places this provider in the 95th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 153 | $180,621 |
| FarxigaDapagliflozin Propanediol | 124 | $128,046 |
| JardianceEmpagliflozin | 105 | $106,551 |
| XareltoRivaroxaban | 48 | $45,924 |
| EliquisApixaban | 37 | $44,787 |
| OzempicSemaglutide | 33 | $42,130 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $37,579 |
| TrulicityDulaglutide | 30 | $37,345 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 28 | $35,200 |
| MyrbetriqMirabegron | 29 | $26,533 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $18,646 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $17,710 |
| Xigduo XrDapaglifloz Propaned/Metformin | 31 | $15,909 |
| RybelsusSemaglutide | 16 | $14,409 |
| VascepaIcosapent Ethyl | 26 | $13,808 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,278 | $217,966183 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $840 | $141,751133 claims |
| AstraZenecaFarxiga | $1,606 | $128,046124 claims |
| Novo NordiskOzempic, Rybelsus | $1,461 | $56,53949 claims |
| Johnson & JohnsonXarelto | $799 | $45,92448 claims |
| PfizerEliquis | $529 | $44,78737 claims |
| GSKTrelegy Ellipta, Shingrix | $715 | $39,68642 claims |
| Astellas Pharma US IncMyrbetriq | $36 | $26,53329 claims |
| NovartisEntresto | $105 | $10,18712 claims |
| AbbVieSynthroid | $940 | $4,70643 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Senatobia
- Russell CarlisleWesson$1.6M
- Keith StokesLexington$654K
- Walter CarnahanSouthaven$146K
- Karen WhitneyWhitfield$117K
- Dava ClevelandJackson$100K
- Andrea PhillipsJackson$96K
- Kristi TrimmRidgeland$34K
- Tana CooperBiloxi$25K
- Delora DenneyPicayune$24K
- Randall HulingOlive Branch$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.